CoChat

Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease.

Mara, Arlind B., Gavitt, Tyler D., Tulman, Edan R., Geary, Steven J., Szczepanek, Steven M. · 2020 · npj Vaccines
Cited by 24

The DOI matches its Crossref record.

Abstract

Vaccine-enhanced disease (VED) occurs as a result of vaccination followed by infection with virulent Mycoplasma pneumoniae. To date VED has prevented development of an efficacious vaccine against this significant human respiratory pathogen. Herein we report that vaccination of BALB/c mice with M. pneumoniae lipid-associated membrane proteins (LAMPs) induces lung lesions consistent with exacerbated disease following challenge, without reducing bacterial loads. Removal of lipid moieties from LAMPs prior to vaccination eliminates VED and reduces bacterial loads after infection. Collectively, these data indicate that lipid moieties of lipoproteins are the causative factors of M. pneumoniae VED.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41541-020-0181-x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. Waites, K. B. et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin. Microbiol. Rev. 30, 747–809 (2017). · DOI · Paper page
  2. Bajantri, B., Toolsie, O., Venkatram, S. & Diaz-Fuentes, G. Mycoplasma pneumoniae pneumonia: walking pneumonia can cripple the susceptible. J. Clin. Med. Res. 10, 891–897 (2018). · doi:10.14740/jocmr3592w
  3. Marrie, T. J. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch. Intern Med. 153, 488–494 (1993). · doi:10.1001/archinte.1993.00410040054008
  4. Niederman, M. S. & Brito, V. Pneumonia in the older patient. Clin. Chest Med. 28, 751–771 (2007). · DOI
  5. Khoury, T. et al. Increased rates of intensive care unit admission in patients with Mycoplasma pneumoniae: a retrospective study. Clin. Microbiol Infect. 22, 11–714 (2016). · DOI
  6. Liu, X. et al. Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics. Biomed. Res Int. https://doi.org/10.1155/2014/320801 (2014). · DOI
  7. Bebear, C., Pereyre, S. & Peuchant, O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 6, 423–431 (2011). · DOI · Paper page
  8. Smith, C. B., Friedewald, W. T. & Chanock, R. M. Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers. J. Am. Med. Assoc. 199, 353–358 (1967). · doi:10.1001/jama.1967.03120060051007
  9. Smith, C. B., Chanock, R. M., Friedewald, W. T. & Alford, R. H. Mycoplasma pneumoniae infections in volunteers. Ann. N. Y. Acad. Sci. 143, 471–483 (1967). · DOI
  10. Szczepanek, S. M. et al. Vaccination of BALB/c mice with an avirulent Mycoplasma pneumoniae P30 mutant results in disease exacerbation upon challenge with a virulent strain. Infect. Immun. 80, 1007–1014 (2012). · DOI
  11. Kurai, D. et al. Mycoplasma pneumoniae extract induces an IL-17-associated inflammatory reaction in murine lung: implication for mycoplasmal pneumonia. Inflammation 36, 285–93 (2013). · DOI
  12. Kurata, S. et al. Role of IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae. BMC Microbiol. 14, 156 (2014). · DOI
  13. Chu, H. W. et al. Repeated respiratory Mycoplasma pneumoniae infections in mice: effect of host genetic background. Microbes Infect. 8, 1764–1772 (2006). · doi:10.1016/j.micinf.2006.02.014
  14. Proft, T. & Herrmann, R. Identification and characterization of hitherto unknown Mycoplasma pneumoniae proteins. Mol. Microbiol. 13, 337–348 (1994). · DOI
  15. Regula, J. T. et al. Defining the mycoplasma cytoskeleton: the protein composition of the Triton X-100 insoluble fraction of the bacterium Mycoplasma pneumoniae determined by 2-D gel electrophoresis and mass spectrometry. Microbiology 147, 1045–1057 (2001). · DOI
  16. Beghetto, E., De Paolis, F., Montagnani, F., Cellesi, C. & Gargano, N. Antobody response to Mycoplasma pneumoniae: protection of host and influence on outbreaks? Microbes Infect. 11, 66–73 (2009). · DOI
  17. Nuyttens, H., Cyncynatus, C., Renaudin, H., Pereyre, S. & Bebear, C. Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae. BMC Microbiol. 10, 216 (2010). · DOI
  18. Szczepanek, S. M. et al. Identification of lipoprotein MslA as a neoteric virulence factor of Mycoplasma gallisepticum. Infect. Immun. 78, 3475–3483 (2010). · DOI · Paper page
  19. Masukagami, Y. et al. The Mycoplasma gallisepticum virulence factor lipoprotein MslA is a novel polynucleotide binding protein. Infect. Immun. 81, 3220–3226 (2013). · DOI
  20. Zuo, L. L., Wu, Y. M. & You, X. X. Mycoplasma lipoproteins and toll-like receptors. J. Zhejiang Univ. Sci. B. 10, 67–76 (2009). · DOI
  21. Rosenbusch, R. Test of an inactivated vaccine against Mycoplasma bovis respiratory disease by transthoracic challenge with an abscessing strain. Abstracts of the 12th International Organization of Mycoplasmology Conference, Sydney, Australia, 185 (1998).
  22. Bryson, D., Ball, H. J., Brice, N., Pollock, D. S. & Forster, F. Pathology of induced Mycoplasma bovis pneumonia in experimentally vaccinated calves. Mycoplasmas Ruminants: Pathogenicity, Diagnostics, Epidemiol. Mol. Genet. 3, 128–132 (1998).
  23. Mulongo, M. et al. Vaccination of cattle with the LppQ-N’ sub-unit of Mycoplasma mycoides subsp. mycoides results in type III immune complex disease upon experimental infection. Infect. Immun. 83, 1992–2000 (2015). · doi:10.1128/iai.00003-15
  24. Bordier, C. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 25;256, 1604–1607 (1981). · DOI · Paper page
  25. Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359–362 (2009). · DOI · Paper page
  26. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b- range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–72 (2008). · DOI · Paper page
  27. Hallamaa, K. M., Browning, G. G. & Tang, S. L. Lipoprotein multigene families in Mycoplasma pneumoniae. J. Bacteriol. 188, 5393–5399 (2006). · DOI
  28. Bartosh, T. J. & Ylostalo, J. H. Macrophage inflammatory assay. Bio. Protoc. 4, https://doi.org/10.21769/bioprotoc.1180 (2014). · DOI
  29. Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res https://doi.org/10.1093/nar/gky1106 (2019). · DOI · Paper page

Cited by

See all 24

Metadata

Authors
Mara, A. B., Gavitt, T. D., Tulman, E. R., Geary, S. J., & Szczepanek, S. M.
Venue
npj Vaccines
Published
2020-04-08
Volume
5
Issue
1
ISSN
2059-0105
Cited by
24
References
0
Language
en
Licence
Funders
This study was funded in part by funds made available by the Center of Excellence for Vaccine Research (S.J.G) and through a UConn OVPR START Grant (S.M.S).

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease. https://app.cochat.ai/papers/10.1038/s41541-020-0181-x
The paper
Mara, A. B., Gavitt, T. D., Tulman, E. R., Geary, S. J., & Szczepanek, S. M. (2020). Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease. npj Vaccines. https://doi.org/10.1038/s41541-020-0181-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.